• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review
Conclusion: The findings of this systematic review have provided a better understanding of the possible association between cardiotoxicities and anticancer drugs for NSCLC. Whilst variation is observed across different drug classes, the lack of information available on cardiac monitoring can result in underestimation of this association.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020191760, identifier PROSPERO CRD42020191760.
Source: Frontiers in Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42.FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67-69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58-0·84]; p<0·0001), with 5-year overall ...
Source: Cancer Control - March 29, 2023 Category: Cancer & Oncology Authors: Christopher J Sweeney Andrew J Martin Martin R Stockler Stephen Begbie Leanna Cheung Kim N Chi Simon Chowdhury Mark Frydenberg Lisa G Horvath Anthony M Joshua Nicola J Lawrence Gavin Marx John McCaffrey Ray McDermott Margaret McJannett Scott A North Franc Source Type: research

Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
CONCLUSION: Platinum-based chemotherapy with BEV followed by BEV maintenance for platinum-sensitive recurrence during PARP inhibitor treatment was shown to be efficacious and safe. This combination should be further evaluated in larger randomized clinical trials.PMID:36854492 | DOI:10.21873/anticanres.16273
Source: Cancer Control - February 28, 2023 Category: Cancer & Oncology Authors: Marina Abe Tadahiro Shoji Yohei Chiba Eriko Takatori Yoshitaka Kaido Takayuki Nagasawa Masahiro Kagabu Fumiaki Takahashi Takeshi Aida Tsukasa Baba Source Type: research

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
CONCLUSION: The combination of apatinib with docetaxel followed by epirubicin plus cyclophosphamide showed excellent efficacy and manageable toxicities; and further randomized controlled phase III trials are warranted.TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov (NCT03243838) on 5 August 2017.PMID:35983024 | PMC:PMC9379563 | DOI:10.1177/17588359221118053
Source: Cancer Control - August 19, 2022 Category: Cancer & Oncology Authors: Ciqiu Yang Junsheng Zhang Yi Zhang Fei Ji Yitian Chen Teng Zhu Liulu Zhang Hongfei Gao Mei Yang Jieqing Li Minyi Cheng Kun Wang Source Type: research

Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism
J Clin Invest. 2022 May 26:e149117. doi: 10.1172/JCI149117. Online ahead of print.ABSTRACTCardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and identify novel therapeutic targets.We studied arteries from postmenopausal women who had undergone breast cancer treatment using docetaxel, doxorubicin and cyclophosphamide (NACT), and women with no history of such treatment matched for key clinical parameters. Mechanisms were explored in ...
Source: Clinical Genitourinary Cancer - May 26, 2022 Category: Cancer & Oncology Authors: Piotr Szczepaniak Mateusz Siedlinski Diana Hodorowicz-Zaniewska Ryszard Nosalski Tomasz P Mikolajczyk Aneta M Dobosz Anna Dikalova Sergey Dikalov Joanna Streb Katarzyna Gara Pawel Basta Jaroslaw Krolczyk Joanna Sulicka-Grodzicka Ewelina Jozefczuk Anna Dzi Source Type: research

Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients
CONCLUSIONS: Both neoadjuvant regimens are effective and tolerable in patients with HER2+ BC. The PH-FECH regimen offers a higher pCR rate and higher PFS but no difference in overall survival or breast cancer-specific survival. Higher frequency of cardiac toxicity with PH-FECH was noted.PMID:34312098 | DOI:10.1016/j.clbc.2021.05.008
Source: Clinical Genitourinary Cancer - July 27, 2021 Category: Cancer & Oncology Authors: Xuexin He Xiaolan Dai Jiali Ji Hong Liu Ganggang Shi Sai-Ching Jim Yeung Source Type: research

Ramucirumab in the treatment of non-small cell lung cancer.
Authors: Oscar A, Zyanya Lucia ZB, Andres FC, Amir C, Mariana LM Abstract INTRODUCTION: Therapeutic options for treating Non-Small Cell Lung Cancer (NSCLC) have recently increased. Ramucirumab (Cyramza), an anti-angionenic agent was approved in 2014 for treatment of several malignancies, including second-line treatment of patients with NSCLC with disease progression on or after platinum-based chemotherapy. Areas covered: We performed a comprehensive search of the literature focused on clinical trials with use of ramucirumab, targeting its evolution in the treatment of NSCLC. This review summarizes the results regar...
Source: Expert Opinion on Drug Safety - April 13, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Abstract P6-14-03: Genome wide association study (GWAS) to identify variants conferring ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
Background: In a candidate single nucleotide polymorphism (SNP) association study, we previously identified VEGFR-1 and VEGFR-2 SNPs strongly associated with treatment emergent hypertension (HT) in the ramucirumab (RAM) and docetaxel (Doc) arm in the ROSE/TRIO-012 study, a double-blinded multinational phase III trial that randomized 1,144 patients with advanced breast cancer to receive first-line Doc in combination with RAM or placebo (Mackey et al, JCO Jan 10, 2015:141-148; Mackey et al, JCO, Volume 33, Issue 15_suppl, May 20, 2015: 547). However, candidate SNP studies limit the number of genes for interrogation and a mor...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Mackey, J., Lipatov, O., Martin, M., Webster, M., Hegg, R., Verma, S., Ramos–Vazquez, M., Fresco, R., Thireau, F., Houe, V., Press, M., Kumaran, M., Damaraȷu, S. Tags: Poster Session Abstracts Source Type: research